Published on: October 21, 2024

Published on 21 October 2024

As of 21 October 2024, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible inclusion in the Philippine National Formulary (PNF) and thus the government financing of the following health technologies, for stakeholder feedback/comments:

  • Dapivirine vaginal ring 25 mg vaginal delivery system for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in adult women specifically as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches (e.g., oral PrEP).
  • Donepezil hydrochloride 23 mg film-coated tablet for moderate to severe Alzheimer’s disease
  • Tenofovir/ Lamivudine/ Dolutegravir 300mg/300mg/50 mg tablet for HIV treatment for treatment-experienced people living with HIV (PLHIV) (including those that are stable in their current regimen)
  • Tenofovir + Lamivudine 300mg / 300mg tablet in combination with Dolutegravir 50 mg tablet for HIV treatment for treatment-experienced people living with HIV (PLHIV) (including those that are stable in their current regimen)

These health technologies were reviewed against national clinical practice guidelines (CPGs) [local and approved by the Department of Health (DOH); and/or international, but locally adopted guidelines], existing recommendations by the World Health Organization (WHO), and DOH Omnibus Health Guidelines (OHG). Further, costing analyses of these health technologies were performed. The supporting evidence reviewed and discussed by the HTA Council are shown below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 05 November 2024 (Tuesday), for the consideration of the HTA Council, through email at hta@dost.gov.ph.

Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us through the same email address or via telephone call via (02) 8651-7800 local 2410.

Preliminary-HTA-Council-Recommendation-on-Dapivirine-Donepezil-and-Tenofovir-21-October-2024Download